Although osimertinib treatment potently decreases DR4 levels in the sensitive EGFRm NSCLC cell lines, we detected much higher levels of DR4 in HCC827/AR, HCC827/ER, PC-9/GR, PC-9/GR/AR and PC-9/3M resistant cell lines than in their corresponding parental cell lines (Figure 5A). The gene discussed is TNFRSF10A; the disease is non-small cell lung carcinoma.